- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mayo Clinic | Strategic Alliance Partners
Latest from Mayo Clinic
Liquid Biopsies, ctDNA Could Help Guide Gastrointestinal Cancer Management
November 19, 2024
Article
Tanios S. Bekaii-Saab, MD, discusses the role of liquid biopsies and ctDNA in gastrointestinal cancers.
Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer
November 17, 2024
Article
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More
November 06, 2024
Article
Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.
Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research
November 04, 2024
Article
Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.
Dr Nowakowski on the Significance of the TakeAim Lymphoma Trial in PCNSL
October 17, 2024
Video
Grzegorz S. Nowakowski, MD, discusses the potential implications of the TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with PCNSL.
Dr Nowakowski on the Implications of the FDA Approval of Epcoritamab in Follicular Lymphoma
October 17, 2024
Video
Grzegorz S. Nowakowski, MD, discusses the clinical implications of the FDA approval of third-line epcoritamab for relapsed/refractory follicular lymphoma.
Emavusertib Plus Ibrutinib Is Under Investigation in the TakeAim Trial in PCNSL
October 07, 2024
Article
Grzegorz S. Nowakowski, MD, discusses the methods and objectives of the part B expansion portion of the TakeAim Lymphoma study in patients with PCNSL.
Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm
October 04, 2024
Article
Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.
Mayo Clinic to Expand Access to State-of-the-Art Cancer Care Through Transformational Gift
October 03, 2024
Article
Mayo Clinic will enhance and expand access to cancer care and clinical trials for patients and communities, thanks to a philanthropic commitment.
Using a Molecular Scissors to Improve CAR T-Cell Therapy
September 30, 2024
Article
Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.
As Blood Cancer Treatments Evolve, So Does The Patient Journey
September 25, 2024
Article
Treatment for blood cancers is advancing, giving more options to people living with the disease.
Understanding CAR T-Cell Therapy for Cancer: Mayo Clinic Expert Explains How It Works
September 18, 2024
Article
Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.
Dr Nowakowski on Unmet Needs to be Addressed in R/R Follicular Lymphoma
September 13, 2024
Video
Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.
Mayo Clinic Study Finds Dysfunctional White Blood Cells Linked to Heightened Melanoma Risk
September 10, 2024
Article
About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.
Dr Nowakowski on Monitoring Epcoritamab-Associated ICANS and CRS in Follicular Lymphoma
September 10, 2024
Video
Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.
Dr Nowakowski on the Potential Benefit of Epcoritamab in Relapsed/Refractory FL
September 09, 2024
Video
Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.
Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL
September 09, 2024
Article
Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.
Clinical Pearls and Impacts to Practice from EHA 2024
September 05, 2024
Video
The panel concludes by offering final thoughts and insights on recent advancements from EHA 2024.
Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma
September 04, 2024
Video
Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.
Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
August 29, 2024
Video
Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.